Humans will be genetically modified for the first time in Europe after regulators have given the go-ahead to trial DNA-splicing therapy. A destructive blood disorder known as beta thalassaemia, which reduces the production of hemoglobin, could be cured using this therapy. Hemoglobin carries the oxygen the body needs to its cells and without sufficient amounts, those with the disease can be left with bone
deformities, anemia, slow growth, fatigue and shortness of breath. Scientists at the biotech company Crispr hope that they can alter the body’s code to stop the genetic mutation and restore healthy levels of hemoglobin. The disease is the first to be treated using this method in Europe and experts have said that the trials hold promise. READ MORE
